Johnson & Johnson (JNJ)
Cramer's Mad Dash: Johnson & Johnson
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
JNJ Halts Development of Depression Drug Over Efficacy Concerns
While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack of sufficient efficacy.
3 Dividend Kings Shaking Off Market Woes
While the market throws its tariff tantrum, several long-established companies with years of operational success have seen their shares move higher, displaying relative strength.
J&J to stop late-stage study of add-on depression drug
Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive disorder due to insufficient efficacy in the target patient population.
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Buy Johnson & Johnson (JNJ) Stock for Higher Highs?
Amid recent market volatility, Johnson & Johnson (JNJ) stock hit new 52-week highs of nearly $170 on Tuesday.
Johnson & Johnson (JNJ) Presents at 45th Annual TD Cowen Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) 45th Annual TD Cowen Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Conference Call Participants Josh Jennings - TD Cowen Josh Jennings Good morning. We are moving down the medical device track even further on Day Two of the TD Cowen 45th Annual Healthcare Conference.
Johnson & Johnson Just Paid Investors: Here's How Much They Got
Johnson & Johnson (NYSE: JNJ) is rewarding its shareholders once again with a quarterly dividend of $1.24, payable on Tuesday, March 4.
Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today
Johnson & Johnson (JNJ) reachead $167.28 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.
3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income
Generating passive income is a core aspect of my financial strategy. My goal is to eventually produce enough recurring investment income to cover my basic living expenses.
3 Dividend Stocks That Are No-Brainer Buys Right Now
It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
